All In Biotech

Drug Trial Radar · NCT06112743

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

63

Actual

Start

Jan 24, 2024

Primary completion

Jul 16, 2026

Study completion Jun 10, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].

Conditions

  • Cardiomyopathy, Hypertrophic

Interventions

  • MavacamtenDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48Time frame: At week 48

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • Local Institution - 0087

    West Hollywood, California

  • Local Institution - 0003

    Atlanta, Georgia

  • Local Institution - 0093

    Boston, Massachusetts

  • Local Institution - 0090

    Cleveland, Ohio

  • Local Institution - 0086

    Pittsburgh, Pennsylvania

  • Local Institution - 0017

    Houston, Texas

  • Local Institution - 0035

    Murray, Utah

  • Local Institution - 0080

    Buenos Aires, Argentina

  • Local Institution - 0076

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0075

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0079

    Pilar, Buenos Aires, Argentina

  • Local Institution - 0077

    Córdoba, Córdoba Province, Argentina

  • Local Institution - 0074

    Rosario, Santa Fe Province, Argentina

  • Local Institution - 0015

    Camperdown, New South Wales, Australia

  • Local Institution - 0085

    Chermside, Queensland, Australia

  • Local Institution - 0005

    Melbourne, Victoria, Australia

  • Local Institution - 0001

    Montreal, Quebec, Canada

  • Local Institution - 0068

    Québec, Quebec, Canada

  • Local Institution - 0061

    Geneva, Switzerland

  • Local Institution - 0024

    Zürich (de), Switzerland

  • Local Institution - 0058

    Lucerne, Luzern (de), Switzerland

  • Local Institution - 0029

    Lugano, Ticino (it), Switzerland

  • Local Institution - 0025

    Leeds, Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.